A retrospective study of pulmonary infarction in patients with systemic lupus erythematosus from southern Taiwan

Lupus

Volumn 20, Issue 8, 2011, Pages 876-885

  Weng, C T ^a   Chung, T J ^a   Liu, M F ^a   Weng, M Y ^a   Lee, C H ^a   Chen, J Y ^a   Wu, A B ^a   Lin, B W ^a   Luo, C Y ^a   Hsu, S C ^a   Lee, B F ^a   Tsai, H M ^a   Chao, S C ^a   Wang, J Y ^a   Chen, T Y ^a   Chen, C W ^a   Chang, H Y ^a   Wang, C R ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiphospholipid syndrome; Pulmonary infarction; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADD ON THERAPY; ADOLESCENT; ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTERY EMBOLISM; ARTICLE; BLOOD CLOT LYSIS; CENTRAL PULMONARY ARTERY EMBOLISM; CORTICOSTEROID THERAPY; DEEP VEIN THROMBOSIS; FEMALE; HOSPITALIZATION; HUMAN; INFERIOR VENA CAVA THROMBOSIS; LUNG EMBOLISM; LUNG INFARCTION; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TAIWAN; THORAX RADIOGRAPHY; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ADULT; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; LUNG; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PULMONARY INFARCTION; RETROSPECTIVE STUDIES; TAIWAN; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 80052764229     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311401458     Document Type: Article

References (58)

1. Bertoli AM, Vila LM, Apte M, et al. Systemic lupus erythematosus in a multiethnic US Cohort LUMINA XLVIII: factors predictive of pulmonary damage. Lupus 2007; 16: 410-417. (Pubitemid 47122214)
2. Pego-Reigosa JM, Medeiros DA, Isenberg DA. Respiratory manifestations of systemic lupus erythematosus: old and new concepts. Best Pract Res Clin Rheumatol 2009; 23: 469-480.
3. Quadrelli SA, Alvarez C, Arce SC, et al. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus 2009; 18: 1053-1060.
4. Liu MF, Lee JH, Weng TH, Lee YY. Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol 1998; 27: 291-295.
5. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.
6. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-1509.
7. Hughes GRV. Antiphospholipid syndrome (Hughes syndrome): 10 clinical topics. Lupus 2010; 19: 343-346.
8. Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunological manifestations and pattern of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027. (Pubitemid 34303815)
9. Stojanovich L. Pulmonary manifestations in antiphospholipid syndrome. Autoimmun Rev 2006; 5: 344-348. (Pubitemid 43868201)
10. Howe HS, Boey ML, Fong KY, Feng PH. Pulmonary haemorrhage, pulmonary infarction, and the lupus anticoagulant. Ann Rheum Dis 1988; 47: 869-872.
11. Erkan D, Yazici Y, Sobel R, Lockshin MD. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 2000; 27: 2817-2821.
12. Bertoli AM, Tabares AH, Casas JP, Saurit V, Caeiro F, Alvarellos A. Lung cavitation in primary antiphospholipid syndrome. Lupus 2002; 11: 57-59. (Pubitemid 34178123)
13. Weng CT, Cheng LL, Wang CR. Pulmonary infarctions due to bilateral pulmonary arterial thrombosis in a lupus patient with antiphospholipid syndrome. J Rheumatol 2008; 35: 2064-2065.
14. Khan AN, Al-Jahdali H, Al-Ghanem S, Gouda A. Reading chest radiographs in the critically ill (Part II): Radiography of lung pathologies common in the ICU patient. Ann Thorac Med 2009; 4: 149-157.
15. Chiu YM, Lai CH. Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus 2010; 19: 1250-1255.
16. Liou HH, Wang CR, Chen CJ, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996; 5: 307-312.
17. Lai NS, Lan J. Renal vein thrombosis in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 1997; 56: 562-564. (Pubitemid 27428480)
18. Tsai MH, Tsai WP, Liao ST, Liou LB. Anticardiolipin antibodies in various diseases in Taiwan: a retrospective analysis. Lupus 2003; 12: 747-753.
19. Yang YH, Chang CJ, Chuang YH, Hsu HY, Chen PP, Chiang BL. Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. Rheumatology 2010; 49: 34-42.
20. Weng CT, Lee NY, Liu MF, et al. A retrospective study of catastrophic invasive fungal infections in patients with systemic lupus erythematosus from southern Taiwan. Lupus 2010; 19: 1204-1209.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
22. Dalen JE, Haffajee CI, Alpert JS, et al. Pulmonary embolism, pulmonary hemorrhage and pulmonary infarction. N Engl J Med 1977; 296: 1431-1435. (Pubitemid 8175592)
23. Stoll T, Seifert B, Isenberg DA. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Br J Rheumatol 1996; 35: 248-254.
24. Brims FJ, Davies HE, Lee YC. Respiratory chest pain: diagnosis and treatment. Med Clin North Am 2010; 94: 217-232.
25. Goldhaber SZ. Pulmonary embolism. Lancet 2004; 363: 1295-1305. (Pubitemid 38496494)
26. Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358: 1037-1052.
27. Agnelli G, Becattini C. Acute pulmonary embolism. N Engl J Med 2010; 363: 266-274.
28. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774-2782. (Pubitemid 41369106)
29. Molina JA, Jiang ZG, Heng BH, Ong BK. Venous thromboembolism at the National Healthcare Group, Singapore. Ann Acad Med Singapore 2009; 38: 470-478.
30. Lee CH, Lin LJ, Cheng CL, Kao Yang YH, Chen JY, Tsai LM. Incidence and cumulative recurrence rates of venous thromboembolism in the Taiwanese population. J Thromb Haemost 2010; 8: 1515-1523.
31. Chen TY, Su WC, Tsao CJ. Incidence of thrombophilia detected in southern Taiwanese patients with venous thrombosis. Ann Hematol 2003; 82: 114-117.
32. Porcel JM, Light RW. Pleural effusions due to pulmonary embolism. Curr Opin Pulm Med 2008; 14: 337-342. (Pubitemid 351786546)
33. Doria A, Iaccarino L, Sarzi-Puttini P, Atzeni F, Turriel M, Petri M. Cardiac involvement in systemic lupus erythematosus. Lupus 2005; 14: 683-686. (Pubitemid 41413291)
34. Asherson R, Khamashta M, Ordi-Rios J, et al. The primary antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366-374. (Pubitemid 19286656)
35. Palla A, Donnamaria V, Petruzzelli S, Rossi G, Riccetti G, Giuntini C. Enlargement of the right descending pulmonary artery in pulmonary embolism. Am J Roentgenol 1983; 141: 513-517. (Pubitemid 13039900)
36. Tsao MS, Schraufnagel D, Wang NS. Pathogenesis of pulmonary infarction. Am J Med 1982; 72: 599-606. (Pubitemid 12089334)
37. Schraufnagel DE, Tsao MS, Yao YT, Wang NS. Factors associated with pulmonary infarction. A discriminant analysis study. Am J Clin Pathol 1985; 84: 15-18. (Pubitemid 15240212)
38. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology and diagnosis. Chest 2002; 122: 1440-1456. (Pubitemid 35339565)
39. Parker BM, Smith JR. Pulmonary embolism and infarction; a review of the physiologic consequences of pulmonary arterial obstruction. Am J Med 1958; 24: 402-427.
40. Ellis FH, Grindlay JH, Edwards JE. The bronchial arteries. II. Their role in pulmonary embolism and infarction. Surgery 1952; 31: 167-179.
41. Kaushik S, Federle MP, Schur PH, Krishnan M, Silverman SG, Ros PR. Abdominal thrombotic and ischemic manifestations of the antiphospholipid antibody syndrome: CT findings in 42 patients. Radiology 2001; 218: 768-771. (Pubitemid 32172561)
42. André M, Delèvaux I, Amoura Z, Corbi P, Courthaliac C, Aumaître O, Piette JC. Ovarian vein thrombosis in the antiphospholipid syndrome. Arthritis Rheum 2004; 50: 183-186. (Pubitemid 38084303)
43. Fedullo PF, Morris TA. Pulmonary thromboembolism. In: Mason RJ, Broaddus VC, Murray JF, Nadel JA (eds), Murray and Nadel's Textbook of Respiratory Medicine. Philadelphia, PA: WB Saunders; 2005. p. 1428.
44. Arroliga AC, Matthay MA, Matthay RA. Pulmonary thromboembolism and other pulmonary vascular diseases. In: George RB, Light RW, Matthay MA, Matthay RA (eds), Chest Medicine: Essentials of Pulmonary and Critical Care Medicine. Philadelphia, PA: Lippincott Williams and Wilkins; 2005. p. 210.
45. Erkan D, Lockshin MD. New approaches for managing antiphospholipid syndrome. Nature Clin Pract Rheumatol 2009; 5: 160-170.
46. Derksen RH, de Groot PG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010; 19: 470-474.
47. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid- antibody syndrome. N Engl J Med 1995; 332: 993-997.
48. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-1495. (Pubitemid 350308848)
49. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 2004; 116: 435-442. (Pubitemid 38388612)
50. You JH, Chan FW, Wong RS, Cheng G. Is INR between 20 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol 2005; 59: 582-587. (Pubitemid 40632249)
51. Tan BE, Thong BY, Shivananda S, Han WW, Chng HH. Clinical manifestations and outcomes of antithrombotic treatment of the Tan Tock Seng Hospital Singapore antiphospholipid syndrome cohort. Lupus 2009; 18: 752-758.
52. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn 2010; 37: 3-24.
53. You JH, Wong RS, Waye MM, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2011; 31: 113-118.
54. Hughes GRV. Rituximab in lupus and beyond: the state of the art. Lupus 2009; 18: 639-644.
55. Bick RL, Baker WF. Treatment options for patients who have antiphospholipid syndromes. Hematol Oncol Clin North Am 2008; 22: 145-153.
56. Srinivasan SK, Pittelkow MR, Cooper LT. Recombinant tissue plasminogen activator for the treatment of cutaneous infarctions in antiphospholipid antibody syndrome: a case report. Angiology 2001; 52: 635-639. (Pubitemid 32880114)
57. La Milia V, Tentori F, Pozzi C, Taddei G, Locatelli F. Primary antiphospholipid antibody syndrome with membranous obstruction of the inferior vena cava-successful PTA and thrombolytic therapy. Nephrol Dial Transplant 1998; 13: 2641-2644. (Pubitemid 28445887)
58. Harpaz D, Glikson M, Sidi Y, Hod H. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. Am Heart J 1991; 122: 1492-1495.